CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Canbridge Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Canbridge Pharmaceuticals Inc
Rongchuang Roadchaoyang District
Suite 301, 3f, Timeloit No.17
Phone: +86 1084148018p:+86 1084148018 SUZHOU, JNG  02142-1530  China Ticker: 12281228
Business Summary
CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, Founder QunXue 54 6/21/2021 1/1/2018
Chief Financial Officer GlennHassan 45 4/1/2019 4/1/2019
Joint Company Secretary QianMa 1/1/2020 1/1/2020
6 additional Officers and Directors records available in full report.

Business Names
Business Name
1228
MF1

General Information
Number of Employees: 100 (As of 12/31/2023)
Outstanding Shares: 424,838,320 (As of 1/31/2024)
Stock Exchange: HKG
Fax Number: +86 1084148017


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024